Objective: To understand long-term survival rate after combined androgen blockade(CAB) in patients with advanced prostate cancer.Methods: A selected population of 59 patients with advanced prostate cancer were treated with CAB.(28.81)%(17/59) of patients had clinical locally advanced disease(stage T3-4N0M0),and(45.76)%(27/59) of patients had metastatic disease(stage TxNxM+).Overall,patients were followed for a median of 62(range 6-136) months.Results: Of the 59 patients with advanced prostate cancer,3-year,...